DiaMedica to Present at the 16th Annual Biotech in Europe Forum for Global Partnering and Investment Conference
(firmenpresse) - MINNEAPOLIS, MINNESOTA -- (Marketwired) -- 09/26/16 -- DiaMedica Inc. (the "Company") (TSX VENTURE: DMA)(OTCQB: DMCAF), a biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will present at the 16th Annual Biotech in Europe Forum for Global Partnering and Investment Conference being held September 27-28, 2016 at the Congress Center, Basel, Switzerland. Mr. Rick Pauls, President and CEO of DiaMedica, will present on Tuesday September 27, 2016 at 9:30am CET.
The Annual Biotech in Europe Forum for Global Partnering and Investment brings together a cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. For more information, visit .
About DiaMedica
DiaMedica is a publicly-traded clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica''s shares are listed on the TSX Venture Exchange under the trading symbol "DMA" and on the OTCQB under the trading symbol "DMCAF".
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica''s expectations, should be considered forward-looking statements. Such statements are based on management''s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. Forward looking statements in this news release include, but are not limited to, the Company''s objectives, goals, future plans and statements regarding the use of proceeds from the private placement. Factors that could cause actual results to differ materially from such forward-looking information described in detail in the DiaMedica''s filings with the Canadian securities regulators, all of which are available on SEDAR (). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.
Contacts:
DiaMedica Inc.
Donna Husemoller
Corporate Controller
Two Carlson Parkway, Suite165, Minneapolis, MN
763-270-0603
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.09.2016 - 06:00 Uhr
Sprache: Deutsch
News-ID 1460189
Anzahl Zeichen: 3635
contact information:
Contact person:
Town:
MINNEAPOLIS, MINNESOTA
Phone:
Kategorie:
Hospitals, Facilities and Providers
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 401 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DiaMedica to Present at the 16th Annual Biotech in Europe Forum for Global Partnering and Investment Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
DiaMedica Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
